Current Therapy in Internal Medicine

por Allison, S. P.
Publicado 1992

Debate: Albumin administration should not be avoided

por Allison, Simon P, Lobo, Dileep N
Publicado 2000

Cellular secretion studied by force microscopy

por Allison, D P, Doktycz, M J
Publicado 2006

Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells

por Loke, P'ng, Allison, James P
Publicado 2004

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection

por Waitz, Rebecca, Fassò, Marcella, Allison, James P.
Publicado 2012

TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion

por Sharma, Naveen, Vacher, Jean, Allison, James P.
Publicado 2019

TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo

por Gottschalk, Rachel A., Corse, Emily, Allison, James P.
Publicado 2010

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Va...

por van Elsas, Andrea, Hurwitz, Arthur A., Allison, James P.
Publicado 1999

LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy

por Sharma, Naveen, Atolagbe, Oluwatomisin T., Ge, Zhongqi, Allison, James P.
Publicado 2021

Attenuated T Cell Responses to a High-Potency Ligand In Vivo

por Corse, Emily, Gottschalk, Rachel A., Krogsgaard, Michelle, Allison, James P.
Publicado 2010

Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity

por Wei, Joyce, Loke, P’ng, Zang, Xingxing, Allison, James P.
Publicado 2011

Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes

por Lühder, Fred, Höglund, Petter, Allison, James P., Benoist, Christophe, Mathis, Diane
Publicado 1998

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

por Curran, Michael A., Kim, Myoungjoo, Montalvo, Welby, Al-Shamkhani, Aymen, Allison, James P.
Publicado 2011

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

por Fan, Xiaozhou, Quezada, Sergio A., Sepulveda, Manuel A., Sharma, Padmanee, Allison, James P.
Publicado 2014

Repression of B7.2 on Self-reactive B Cells Is Essential to Prevent Proliferation and Allow Fas-mediated Deletion by CD4(+) T Cells

por Rathmell, Jeffrey C., Fournier, Sylvie, Weintraub, Bennett C., Allison, James P., Goodnow, Christopher C.
Publicado 1998

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

por Peggs, Karl S., Quezada, Sergio A., Chambers, Cynthia A., Korman, Alan J., Allison, James P.
Publicado 2009

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

por Holmgaard, Rikke B., Zamarin, Dmitriy, Munn, David H., Wolchok, Jedd D., Allison, James P.
Publicado 2013

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4

por Holmgaard, Rikke B, Zamarin, Dmitriy, Munn, David H, Wolchok, Jedd D, Allison, James P
Publicado 2013

Itk Negatively Regulates Induction of  T Cell Proliferation by CD28 Costimulation

por Liao, X. Charlene, Fournier, Sylvie, Killeen, Nigel, Weiss, Arthur, Allison, James P., Littman, Dan R.
Publicado 1997

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

por Quezada, Sergio A., Peggs, Karl S., Simpson, Tyler R., Shen, Yuelei, Littman, Dan R., Allison, James P.
Publicado 2008